【Objective】 To compare the short-term metabolic risk in the first-episode young-adult schizophrenia treated with Aripiprazole and Olanzapine. 【Methods】 The open-lable

natural observed

compared method was designed for this study. All of these cases were diagnosed as first-episode schizophrenia in accordance with the DSM-Ⅳ diagnosis criteria and respectively allocated into two groups for either Aripiprazole or Olanzapine treatment. The natural observed period was from two weeks to four weeks. Weight

waist circumference

fasting glucose

and lipid concentration

fasting insulin and C peptide concentration

and insulin resistance index were tested or checked at baseline and endpoint

respectively. 【Results】 Sixty-three young adult first-episode schizophrenia patients were recruited in this study

21 for Aripiprazole (F/M

10/11) and 42 for Olanzapine (F/M

21/21). Weight

BMI

waist circumference and waist/hip increased in Aripiprazole group at endpoint(P < 0.05)

there existed no statistical metabolic index difference between two sex groups (P > 0.05). Weight

BMI

waist circumference and waist/hip

lipid level increased in Olanzapine group at endpoint (P < 0.01). Meanwhile

fasting insulin and IR increased (P < 0.05)

stepwise multiple regression analysis indicated mild positive correlation between IR and TG level(R2 = 0.107

P = 0.007). Fasting insulin

C peptide and IR increased among male patients in Olanzapine group at endpoint(P < 0.05)

although female patients were normal. 【Conclusion】 The results suggested that there existed short-term metabolic risk difference between first-episode young-adult schizophrenia treated with Aripiprazole and Olanzapine

sex difference could play a role in the metabolic risk of SGA.